Pipeline
As we think about the future of medicine, we’re exploring new frontiers across a diverse and robust range of product candidates and disease areas to enable clinicians to Find, Fight and Follow® disease to deliver better patient outcomes. With a strong focus on oncology, neurology and cardiology, and a more than 70-year history as pioneers in radiopharmaceuticals, we are building a focused pipeline aligned to areas of high unmet need.
Pipeline updated September 2026
Oncology
| Candidate | Target | Isotope | Indication/Disease Area | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 | Reg. Filing |
|---|---|---|---|---|---|---|---|---|
| LNTH-2501 | Target: SSTR | Isotope: 68Ga |
Indication/Disease Area: Neuroendocrine tumors |
Phase: Reg. Filing
|
||||
|
LNTH-2501 is a diagnostic kit for the preparation of Ga-68 edotreotide Injection, indicated for use with PET imaging for the localization of somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs) in adult and pediatric patients. |
||||||||
| LNTH-24011 | Target: GRPR | Isotope: 68Ga |
Indication/Disease Area: Prostate cancer |
Phase: Phase 2
|
||||
|
LNTH-2401 is a novel radiodiagnostic targeting the gastrin-releasing peptide receptor. |
||||||||
| LNTH-2503 | Target: CCK2R | Isotope: 68Ga |
Indication/Disease Area: Small cell lung cancer |
Phase: Phase 1
|
||||
|
LNTH-2503 is a highly specific peptide vector radiodiagnostic, which binds to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker in cancers like small cell lung cancer (SCLC). |
||||||||
| LNTH-1363S* | Target: FAP | Isotope: 64Cu |
Indication/Disease Area: Sarcoma/GI |
Phase: Phase 1
|
||||
|
LNTH-1363S is a fibroblast activation protein, copper-64 labeled radiodiagnostic with broad potential imaging applicability and use in oncology. Learn more about our clinical trial. |
||||||||
| LNTH-2507 | Target: Undisc. | Isotope: 68Ga |
Indication/Disease Area: Pancreatic ductal adenocarcinoma |
Phase: Preclinical
|
||||
|
LNTH-2507 is a radiodiagnostic tracer targeting a cell surface molecule for the diagnosis of pancreatic ductal adenocarcinoma (PDAC). |
||||||||
| LNTH-2403 | Target: LRRC15 | Isotope: 177Lu |
Indication/Disease Area: Relapsed/refractory osteosarcoma |
Phase: Phase 1
|
||||
|
LNTH-2403 is a leucine-rich repeat-containing protein 15 targeted radiotherapeutic. It received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for the treatment of osteosarcoma. Learn more about our clinical trial. |
||||||||
| LNTH-2503 | Target: CCK2R | Isotope: 177Lu |
Indication/Disease Area: Small cell lung cancer |
Phase: Phase 1
|
||||
|
LNTH-2503 is a highly specific peptide vector radiotherapeutic, which binds to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker in cancers like small cell lung cancer (SCLC). |
||||||||
| LNTH-24022 | Target: GRPR | Isotope: 177Lu |
Indication/Disease Area: Metastatic prostate cancer |
Phase: Preclinical
|
||||
|
LNTH-2402 is a novel gastrin-releasing peptide receptor targeted radiotherapeutic for solid tumors including prostate, breast, lung and other cancers. |
||||||||
| LNTH-2507 | Target: Undisc. | Isotope: 177Lu |
Indication/Disease Area: Pancreatic ductal adenocarcinoma |
Phase: Preclinical
|
||||
|
LNTH-2507 is a radiotherapeutic targeting a cell surface molecule for the treatment of pancreatic ductal adenocarcinoma (PDAC). |
||||||||
Neurology
| Candidate | Target | Isotope | Indication/Disease Area | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 | Reg. Filing |
|---|---|---|---|---|---|---|---|---|
| NAV-4694* (flutafuranol) | Target: ß amyloid | Isotope: 18F |
Indication/Disease Area: Alzheimer’s disease |
Phase: Phase 3
|
||||
| LNTH-2620/PI-2620 | Target: Tau | Isotope: 18F |
Indication/Disease Area: Alzheimer’s disease |
Phase: Phase 3
|
||||
|
LNTH-2620/PI-2620 is an F-18 labeled small molecule specifically targeting tau used as a radiodiagnostic in conjunction with PET imaging to show aggregated tau protein in people with Alzheimer’s disease and other tauopathies. It binds to both isoforms of tau (4R and 3R/4R repeats). The FDA has granted Fast Track designation for the development of LNTH-2620/PI-2620 in Alzheimer’s disease (AD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Learn more about our clinical trial. |
||||||||
Cardiology
| Candidate | Target | Isotope | Indication/Disease Area | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 | Reg. Filing |
|---|---|---|---|---|---|---|---|---|
| LNTH-2515 (florbetaben) | Target: Amyloid | Isotope: 18F |
Indication/Disease Area: Cardiac AL amyloidosis |
Phase: Phase 3
|
||||
|
LNTH-2515 (florbetaben) is an F-18 labeled radiodiagnostic stilbene derivative that binds to amyloid deposits and is being studied in patients with cardiac amyloidosis. The FDA has granted Fast Track designation for the development of LNTH-2515 (florbetaben) imaging for the diagnosis of AL (amyloid light chain) and ATTR (transthyretin amyloid cardiomyopathy) cardiac amyloidosis. Learn more about our clinical trial. |
||||||||
| LNTH-2513/GP-1 | Target: GPIIb-IIIa | Isotope: 18F |
Indication/Disease Area: Thromboembolism |
Phase: Phase 2
|
||||
|
LNTH-2513/GP-1 is a small F-18 labeled molecule, specifically designed to image active thrombi (new blood clots) by binding to activated GPllb/llla receptors, which are involved in thrombus formation and propagation. LNTH-2513 (GP1) is the first PET tracer shown to be able to detect acute thromboembolic events in humans. |
||||||||
Each of these product candidates is an investigational drug that has not yet been approved as safe and effective.
SSTR, Somatostatin receptor; GRPR, Gastrin-releasing peptide receptor; CCK2R, Cholecystokinin-2 receptor; FAP, Fibroblast activation protein; LRRC15, Leucine-rich repeat-containing protein 15; GPIIb-IIIa, Glycoprotein IIb-IIIa.
1. Also known as 68Ga-RM2. 2. Also known as 177Lu-RM2.
*We are actively partnering with researchers on these assets to provide appropriate biomarkers in relevant studies. If interested, please contact biomarkers@lantheus.com for more information.
